

**Supplementary Table 1: Detailed phenotypical and genetic features of paediatric-onset motor neuropathies.**

	<b>GEMIN5</b> <i>Kour et al, 2021<sup>1</sup></i>	<b>EXOSC9</b> <i>Burns et al, 2018<sup>2</sup></i> <i>Bizzari et al, 2019<sup>3</sup></i> <i>Sakamoto et al, 2021<sup>4</sup></i> <i>Dabaj et al, 2022<sup>5</sup></i>	<b>RBM7</b> <i>Giunta et al, 2016<sup>6</sup></i>	<b>TRIP4</b> <i>Knierim et al, 2016<sup>7</sup></i> <i>Töpf et al, 2021<sup>8</sup></i>	<b>ASCCI</b> <i>Knierim et al, 2016<sup>7</sup></i> <i>Giuffrida et al, 2020<sup>9</sup></i> <i>Lu et al, 2020<sup>10</sup></i> <i>Rosano et al, 2021<sup>11</sup></i>	<b>ADPRHL2</b> <i>Bejler et al 2021<sup>12</sup></i>	<b>NRCAM</b> <i>Kurolap et al, 2022<sup>13</sup></i> <i>Elahi et al, 2023<sup>14</sup></i>	<b>MME</b> <i>Hong et al, 2019<sup>15</sup></i>	<b>UBE3C</b> <i>Gopinath et al, 2007<sup>16</sup></i>	<b>SLC5A6</b> <i>Holling et al, 2022<sup>17</sup></i>	<b>SLC25A21</b> <i>Boczonadi et al, 2018<sup>18</sup></i>	<b>BANFI</b> <i>Marcelot et al, 2023<sup>19</sup></i>	<b>NAGLU</b> <i>Lopergolo et al, 2023<sup>20</sup></i>
<b>Number of cases</b>	>10 from different families	10 from different families	1	6 from 4 families <sup>c</sup>	5 from 4 families <sup>c</sup>	3 <sup>a, b</sup>	2 <sup>b</sup>	1 <sup>a</sup>	9 from single family	5 from 3 families	1	1	1
<b>Age at onset of neuropathy symptoms</b>	Birth – 1 <sup>st</sup> decade	Birth – 3 years	1 month	Birth	Birth	2 <sup>nd</sup> decade <sup>a</sup>	2 <sup>nd</sup> decade	16 years <sup>a</sup>	3 – 40 years	1 <sup>st</sup> – 2 <sup>nd</sup> decade	3 years	3 years	2 years and 6 months
<b>Initial symptoms</b>	Developmental delay ± hypotonia	Developmental delay ± hypotonia	Hypotonia, poor sucking, failure to thrive	Arthro-gryposis multiplex congenita, congenital fractures and neonatal respiratory distress	Arthro-gryposis multiplex congenita, congenital fractures and neonatal respiratory distress	Walking instability, ± fatigue ± atrophy of intrinsic hand muscles distal lower limbs	Distal lower limb weakness	Lower limb weakness	Walking and running difficulties due to lower limb weakness	Fine motor difficulties ± slow walking	Deteriorated walking, frequent falls	Abnormal and clumsy gait	Weakness in upper and lower limbs
<b>Muscle strength</b>	Generalized weakness	Proximal and distal weakness (1 year)	Generalized weakness	Generalized weakness, hypotonia	Generalized weakness, hypotonia	Distal predominant generalized weakness	Distal or distal-predominant weakness	Distal and lower extremity predominant weakness (24 years)	Distal (predominantly in upper extremities) or generalized weakness	Weakness and atrophy in hands, foot drop, proximal muscles are normal (19 years)	Distal weakness	Diffuse muscle weakness that affected legs more than arms, a complete foot drop (8 years)	Widespread weakness, Atrophy of distal parts of extremities (60 years)
<b>Pyramidal signs</b>	Hyperreflexia	-	-	-	-	± (spasticity)	-	-	Rarely (Brisk reflexes, Babinski sign)	Brisk reflexes, Achilles clonus	Brisk reflexes, Achilles clonus	-	-
<b>Sensory signs</b>	NA	-	-	NA	NA	Hypoesthesia in tip toes, diminished position, and vibration	-	-	-	-	-	Slightly decreased cold sensation of toes	Paresthesia, thermal and painful hypoesthesia in limbs

	<b>GEMIN5</b> <i>Kour et al, 2021<sup>1</sup></i>	<b>EXOSC9</b> <i>Burns et al, 2018<sup>2</sup></i>	<b>RBM7</b> <i>Giunta et al, 2016<sup>6</sup></i>	<b>TRIP4</b> <i>Knierim et al, 2016<sup>7</sup></i> <i>Töpf et al, 2021<sup>8</sup></i>	<b>ASCC1</b> <i>Knierim et al, 2016<sup>7</sup></i> <i>Giuffrida et al, 2020<sup>9</sup></i> <i>Lu et al, 2020<sup>10</sup></i> <i>Rosano et al, 2021<sup>11</sup></i>	<b>ADPRHL2</b> <i>Bejer et al 2021<sup>12</sup></i>	<b>NRCAM</b> <i>Kurolap et al, 2022<sup>13</sup></i> <i>Elahi et al, 2023<sup>14</sup></i>	<b>MME</b> <i>Hong et al, 2019<sup>5</sup></i>	<b>UBE3C</b> <i>Gopinath et al, 2007<sup>16</sup></i>	<b>SLC5A6</b> <i>Holling et al, 2022<sup>17</sup></i>	<b>SLC25A21</b> <i>Boczonadi et al, 2018<sup>18</sup></i>	<b>BANFI</b> <i>Marcelot et al, 2023<sup>19</sup></i>	<b>NAGLU</b> <i>Lopergolo et al, 2023<sup>20</sup></i>
						sense in lower legs and hands							
<b>Additional neurological features</b>	Tremor ± ID ± head nodding ± ataxia ± epilepsy ± microcephaly ± respiratory distress ± oculomotor apraxia	Seizures ± psychomotor regression ± tongue fasciculation ± respiratory insufficiency ± nystagmus	Respiratory difficulties	May result in stillbirth	May result in stillbirth	ID ± seizures ± nystagmus ± postural tremor ± restrictive pulmonary function	-	Postural tremor	-	Tremor ± cerebellar signs	Mild facial weakness, tongue fasciculations, decreased FVC	Swallowing and respiratory difficulties	-
<b>Skeletal deformities</b>	CMA ± claw hands	CMA ± joint contractures ± valgus deformities	-	CMA ± multiple fractures	CMA ± multiple fractures ± talipes equinovarus ± joint contractures	Pes cavus ± scoliosis	Pes cavus ± hammer toes ± scoliosis ± hyperlordosis ± claw hands	Pes cavus ± joint contractures	Pes cavus ± hammer toes	-	Claw hands, scoliosis	Scoliosis	-
<b>Systemic features</b>	High-arched narrow palate	Facial dysmorphism ± short stature ± bone fractures ± microcephalia ± failure to thrive ± strabismus ± esotropia	Cachexia	Pleural effusion and chylothorax, biliary calculi and soft tissue emphysema	Tent-shaped mouth, microretrognathia, polyhydramnios, cardiomyopathy, reduced prenatal movements	Growth retardation ± left ventricle hypertrophy ± mitral insufficiency ± micrognathia ± hyperhidrosis ± absent trunk hair	Cataracts	-	-	Dilated cardiomyopathy ± inguinal hernia	Failure to thrive	Poor weight gain	-

	<b>GEMIN5</b> <i>Kour et al, 2021<sup>1</sup></i>	<b>EXOSC9</b> <i>Burns et al, 2018<sup>2</sup></i> <i>Bizzari et al, 2019<sup>3</sup></i> <i>Sakamoto et al, 2021<sup>4</sup></i> <i>Dabaj et al, 2022<sup>5</sup></i>	<b>RBM7</b> <i>Giunta et al, 2016<sup>6</sup></i>	<b>TRIP4</b> <i>Knierim et al, 2016<sup>7</sup></i> <i>Töpf et al, 2021<sup>8</sup></i>	<b>ASCC1</b> <i>Knierim et al, 2016<sup>7</sup></i> <i>Giuffrida et al, 2020<sup>9</sup></i> <i>Lu et al, 2020<sup>10</sup></i> <i>Rosano et al, 2021<sup>11</sup></i>	<b>ADPRHL2</b> <i>Beijer et al 2021<sup>12</sup></i>	<b>NRCAM</b> <i>Kurolap et al, 2022<sup>13</sup></i> <i>Elahi et al, 2023<sup>14</sup></i>	<b>MME</b> <i>Hong et al, 2019<sup>15</sup></i>	<b>UBE3C</b> <i>Gopinath et al, 2007<sup>16</sup></i>	<b>SLC5A6</b> <i>Holling et al, 2022<sup>17</sup></i>	<b>SLC25A21</b> <i>Boczonadi et al, 2018<sup>18</sup></i>	<b>BANFI</b> <i>Marcelot et al, 2023<sup>19</sup></i>	<b>NAGLU</b> <i>Lopergolo et al, 2023<sup>20</sup></i>
<b>Disease course</b>	Static or progressive course	Progressive (3 patients died during the follow-up between 1.5 and 10 years)	Progressive (Died due to respiratory decompensation)	Progressive (lethal in first 2 years), later onset myopathy cases are described	Progressive (lethal in first 2 years), later onset myopathy cases are described	Progressive	NA	NA	NA	Progressive	Progressive course, unable to stand at 18 years	Progressive (Wheelchair use at 10 years)	Slowly progressive
<b>EMG / Nerve conduction studies</b>	Severe neurogenic pattern, motor neuropathy ± SN ± myopathic pattern	Motor neuronopathy	Low CMAPs with chronic early and late re-innervation	NA	NA	Axonal motor polyneuropathy ± mild SN	Segmental neurogenic involvement in L1-S2 and C8-D1, and myopathic motor unit potentials ± SN	Length-dependent motor neuropathy	Slowed tibial conduction in the older patients (range 37–50 m/s) with normal CMAPs	Motor neuropathy ± neuronopathy ±, mixed demyelinating and axonal neuropathy	Severe neurogenic changes	Neurogenic process with diffuse fibrillations and reduced motor responses	Bilateral chronic motor denervation on C7-T1 myotomes
<b>Cranial MRI</b>	Cerebellar or ponto-cerebellar atrophy ± white matter changes	Cerebellar atrophy ± cerebral atrophy ± white matter atrophy	Normal	Hypoplastic cerebellum, necrosis, haemorrhage of occipital cortex	Abnormal cortical gyration, lateral ventricle dilatation, simplified gyral pattern of the frontal lobes and enlargement of the external CSF spaces	Normal or mild white matter hyper-intensity lesions	Normal or arachnoid cyst of the posterior fossa	NA	Normal	NA	Normal	NA	NA
<b>Nerve biopsy</b>	NA	NA	NA	Normal myelination but with loss of unmyelinate	NA	NA	NA	NA	Chronic axonal neuropathy	Normal	Axonopathy with mild and patchy loss of	NA	NA

	<b>GEMIN5</b> Kour et al, 2021 <sup>1</sup>	<b>EXOSC9</b> Burns et al, 2018 <sup>2</sup> <b>Bizzari et al, 2019<sup>3</sup></b> Sakamoto et al, 2021 <sup>4</sup> Dabaj et al, 2022 <sup>5</sup>	<b>RBM7</b> Giunta et al, 2016 <sup>6</sup>	<b>TRIP4</b> Knierim et al, 2016 <sup>7</sup> Töpf et al, 2021 <sup>8</sup>	<b>ASCC1</b> Knierim et al, 2016 <sup>7</sup> Giuffrida et al, 2020 <sup>9</sup> Lu et al, 2020 <sup>10</sup> Rosano et al, 2021 <sup>11</sup>	<b>ADPRHL2</b> Beijer et al 2021 <sup>12</sup>	<b>NRCAM</b> Kurolop et al, 2022 <sup>13</sup> Elahi et al, 2023 <sup>14</sup>	<b>MME</b> Hong et al, 2019 <sup>15</sup>	<b>UBE3C</b> Gopinath et al, 2007 <sup>16</sup>	<b>SLC5A6</b> Holling et al, 2022 <sup>17</sup>	<b>SLC25A21</b> Boczonadi et al, 2018 <sup>18</sup>	<b>BANFI</b> Marcelot et al, 2023 <sup>19</sup>	<b>NAGLU</b> Lopergolo et al, 2023 <sup>20</sup>
				d axons as documented by “empty” pouches							myelinated fibres		
<b>Other investigations</b>	Abnormal EEG	Pronounced streak-like and mixed increase in echogenicity with widespread evidence of active fasciculations in muscle ultrasound Denervation signs in muscle biopsy, normal EEG	Fibre type grouping of small and hypertrophic fibres in muscle biopsy	Reduced fiber size, increased fiber-size variation, clustered type I fibers, atrophy in muscle biopsy	Fiber size variation and atrophy, type I fiber grouping, oxidative rims, type I fiber predominance in muscle biopsies	Intermittent bifrontal theta waves ± fronto-central sporadic epileptiform activity in EEG	Elevated creatine kinase	NA	-	Low serum biotin, muscle biopsy showed neurogenic pattern	Microcytic anemia, lactic aciduria, increased urinary 3-hydroxyisovaleric and glutaric acids, Marginally increased CSF lactate	NA	20% reduced urinary alpha-N-acetylglucosaminidase activity
<b>Overlapping disorder</b>	PCH	PCDID	-	Congenital myopathy	Congenital myopathy	CONSDIAS, PAMP Syndrome	NDD with neuro-muscular and skeletal abnormalities	CMT2T, SCA43?	NDD with absent speech and movement and behavioral abnormalities	SMVTD	-	Nestor-Guillermo progeria syndrome	CMT2V, MPS3B
<b>Zygoty and variants with motor neuronopathy phenotype</b>	Hom H923P, Hom H913R, Hom D704E,	Hom L14P, CH L14P and R161*, CH L80R and R162Lfs*3	Hom P79R	Hom, R254*, Hom R278*, CH R254* and R278*	Hom E53Gfs19*, CH S311* and deletion of exon 5, CH R343* and 10q22.1	Hom V335G, Hom G77T	Hom S134P, Hom Q25*	CH V440_K472 del and, P676L	CSV	Hom S429G, CH R94* and Y162C	Hom L232R	Het G16R	Het A479T

<b>GEMIN5</b> Kour et al, 2021 <sup>1</sup>	<b>EXOSC9</b> Burns et al, 2018 <sup>2</sup>	<b>RBM7</b> Giunta et al, 2016 <sup>6</sup>	<b>TRIP4</b> Knierim et al, 2016 <sup>7</sup> Töpf et al, 2021 <sup>8</sup>	<b>ASCC1</b> Knierim et al, 2016 <sup>7</sup> Giuffrida et al, 2020 <sup>9</sup> Lu et al, 2020 <sup>10</sup> Rosano et al, 2021 <sup>11</sup>	<b>ADPRHL2</b> Beijer et al 2021 <sup>12</sup>	<b>NRCAM</b> Kurolap et al, 2022 <sup>13</sup> Elahi et al, 2023 <sup>14</sup>	<b>MME</b> Hong et al, 2019 <sup>15</sup>	<b>UBE3C</b> Gopinath et al, 2007 <sup>16</sup>	<b>SLC5A6</b> Holling et al, 2022 <sup>17</sup>	<b>SLC25A21</b> Boczonadi et al, 2018 <sup>18</sup>	<b>BANFI</b> Marcelot et al, 2023 <sup>19</sup>	<b>NAGLU</b> Lopergolo et al, 2023 <sup>20</sup>
Hom G683D, Hom S1000P, CH I988F and L1367P, CH I988F and S1311Lfs*7, CH H162R and L1367P	Hom G51R, CH L14P and R212*			micro- deletion, CH Arg156* and c.297-8 T>G								

**Abbreviations:** CH: Compound heterozygous; CMA: Congenital multiplex arthrogyrosis; CMAP: Compound muscle action potential; CMT: Charcot Marie Tooth disease; CONSDIAS: Stress-induced childhood-onset neurodegeneration with variable ataxia and seizures syndrome; CSF: Cerebrospinal fluid; CSV: Complex structural variant; EEG: Electroencephalography; EMG: Electromyography; FVC: Forced vital capacity; Het: Heterozygous; Hom: Homozygous; ID: Intellectual disability; MPS: Mucopolysaccharidosis; MRI: Magnetic resonance imaging; NA: Not applicable; NDD: Neurodevelopmental disorder; PAMP: Episodic psychosis, ataxia, motor neuropathy with pyramidal signs; PCH: Pontocerebellar hypoplasia; SCA: Spinocerebellar ataxia; SN: Sensory neuropathy; SMVTD: Sodium-dependent multivitamin transporter deficiency

<sup>a</sup>: Later-onset cases are excluded

<sup>b</sup>: Cases with neuropathy as a part of complex disease spectrum are excluded

<sup>c</sup>: Cases described as congenital myopathy are excluded

## References

1. Kour S, Rajan DS, Fortuna TR, *et al.* Loss of function mutations in GEMIN5 cause a neurodevelopmental disorder. *Nat Commun.* May 7 2021;12(1):2558. doi:10.1038/s41467-021-22627-w
2. Burns DT, Donkervoort S, Muller JS, *et al.* Variants in EXOSC9 Disrupt the RNA Exosome and Result in Cerebellar Atrophy with Spinal Motor Neuronopathy. *Am J Hum Genet.* May 3 2018;102(5):858-873. doi:10.1016/j.ajhg.2018.03.011
3. Bizzari S, Hamzeh AR, Mohamed M, Al-Ali MT, Bastaki F. Expanded PCH1D phenotype linked to EXOSC9 mutation. *Eur J Med Genet.* Jan 2020;63(1):103622. doi:10.1016/j.ejmg.2019.01.012
4. Sakamoto M, Iwama K, Sekiguchi F, *et al.* Novel EXOSC9 variants cause pontocerebellar hypoplasia type 1D with spinal motor neuronopathy and cerebellar atrophy. *J Hum Genet.* Apr 2021;66(4):401-407. doi:10.1038/s10038-020-00853-2
5. Dabaj I, Hassani A, Burglen L, *et al.* Pontocerebellar Hypoplasia Type 1D: A Case Report and Comprehensive Literature Review. *J Clin Med.* Jul 26 2022;11(15)doi:10.3390/jcm11154335
6. Giunta M, Edvardson S, Xu Y, *et al.* Altered RNA metabolism due to a homozygous RBM7 mutation in a patient with spinal motor neuropathy. *Hum Mol Genet.* Jul 15 2016;25(14):2985-2996. doi:10.1093/hmg/ddw149
7. Knierim E, Hirata H, Wolf NI, *et al.* Mutations in Subunits of the Activating Signal Cointegrator 1 Complex Are Associated with Prenatal Spinal Muscular Atrophy and Congenital Bone Fractures. *Am J Hum Genet.* Mar 3 2016;98(3):473-489. doi:10.1016/j.ajhg.2016.01.006
8. Topf A, Pyle A, Griffin H, *et al.* Exome reanalysis and proteomic profiling identified TRIP4 as a novel cause of cerebellar hypoplasia and spinal muscular atrophy (PCH1). *Eur J Hum Genet.* Sep 2021;29(9):1348-1353. doi:10.1038/s41431-021-00851-8
9. Giuffrida P, Arpa G, Vanoli A, Di Sabatino A. Comment on Jun, S.Y.; *et al.* "Tumor Budding and Poorly Differentiated Clusters in Small Intestinal Adenocarcinoma" *Cancers* 2020, 12, 2199. *Cancers (Basel).* Oct 15 2020;12(10)doi:10.3390/cancers12102982
10. Lu W, Liang M, Su J, *et al.* Novel compound heterozygous pathogenic variants in ASCC1 in a Chinese patient with spinal muscular atrophy with congenital bone fractures 2 : Evidence supporting a "Definitive" gene-disease relationship. *Mol Genet Genomic Med.* May 2020;8(5):e1212. doi:10.1002/mgg3.1212
11. Rosano KK, Wegner DJ, Shinawi M, *et al.* Biallelic ASCC1 variants including a novel intronic variant result in expanded phenotypic spectrum of spinal muscular atrophy with congenital bone fractures 2 (SMABF2). *Am J Med Genet A.* Jul 2021;185(7):2190-2197. doi:10.1002/ajmg.a.62219
12. Beijer D, Agnew T, Rack JGM, *et al.* Biallelic ADPRHL2 mutations in complex neuropathy affect ADP ribosylation and DNA damage response. *Life Sci Alliance.* Nov 2021;4(11)doi:10.26508/lsa.202101057
13. Kurolap A, Kreuder F, Gonzaga-Jauregui C, *et al.* Bi-allelic variants in neuronal cell adhesion molecule cause a neurodevelopmental disorder characterized by developmental delay, hypotonia, neuropathy/spasticity. *Am J Hum Genet.* Mar 3 2022;109(3):518-532. doi:10.1016/j.ajhg.2022.01.004
14. Elahi Z, Soveyzi M, Nafissi S, *et al.* Bi-allelic loss of function variant in the NRCAM gene is associated with motor-predominant axonal polyneuropathy; the second report. *Mol Genet Genomic Med.* Apr 2023;11(4):e2131. doi:10.1002/mgg3.2131

15. Hong D, Fang P, Yao S, *et al.* Variants in MME are associated with autosomal-recessive distal hereditary motor neuropathy. *Ann Clin Transl Neurol.* Sep 2019;6(9):1728-1738. doi:10.1002/acn3.50868
16. Gopinath S, Blair IP, Kennerson ML, Durnall JC, Nicholson GA. A novel locus for distal motor neuron degeneration maps to chromosome 7q34-q36. *Hum Genet.* Jun 2007;121(5):559-64. doi:10.1007/s00439-007-0348-9
17. Holling T, Nampoothiri S, Tarhan B, *et al.* Novel biallelic variants expand the SLC5A6-related phenotypic spectrum. *Eur J Hum Genet.* Apr 2022;30(4):439-449. doi:10.1038/s41431-021-01033-2
18. Boczonadi V, King MS, Smith AC, *et al.* Mitochondrial oxodicarboxylate carrier deficiency is associated with mitochondrial DNA depletion and spinal muscular atrophy-like disease. *Genet Med.* Oct 2018;20(10):1224-1235. doi:10.1038/gim.2017.251
19. Marcelot A, Rodriguez-Tirado F, Cuniasse P, *et al.* A De Novo Sequence Variant in Barrier-to-Autointegration Factor Is Associated with Dominant Motor Neuronopathy. *Cells.* Mar 9 2023;12(6)doi:10.3390/cells12060847
20. Lopergolo D, Salvatore S, Sorrentino V, Malandrini A, Santorelli FM, Battisti C. Early-onset motor polyneuropathy associated with a novel dominant NAGLU mutation. *Neurol Sci.* Apr 2023;44(4):1415-1418. doi:10.1007/s10072-023-06607-0